Investigating the Functional Role of ADIPOR2 in Breast Cancer Cells from Young Females (≤45 Years): Implications for Targeted Therapy
Sooan Lee
Hankuk Academy of Foreign Studies, Yongin, South Korea
Publication date: December 25, 2024
Hankuk Academy of Foreign Studies, Yongin, South Korea
Publication date: December 25, 2024
DOI: http://doi.org/10.34614/JIYRC202428
ABSTRACT
Breast cancer, a leading cause of mortality worldwide, exhibits genetic amplification abnormalities in younger females. This study focuses on ADIPOR2, a gene implicated in membrane integrity, particularly in breast cancer cells of females aged ≤45. The objective is to investigate ADIPOR2's functional role through siRNA knockdown experiments in MCF7 and MDA-MB-231 cell lines. Methods included cBioPortal analysis of 2,145 patients aged ≤45 and 353 patients aged >45 to compare ADIPOR2 amplification rates, followed by siRNA transfection to evaluate cell size and viability. Results show that ADIPOR2 amplification is strongly associated with estrogen and progesterone receptor positivity. Knockdown of ADIPOR2 significantly reduced cell size and viability in both MCF7 and MDA-MB-231 cell lines, suggesting its role in maintaining membrane integrity. These findings demonstrate ADIPOR2 as a potential therapeutic target in breast cancer, especially in hormone receptor-positive cases, by disrupting membrane composition and potentially promoting cancer cell apoptosis.
Breast cancer, a leading cause of mortality worldwide, exhibits genetic amplification abnormalities in younger females. This study focuses on ADIPOR2, a gene implicated in membrane integrity, particularly in breast cancer cells of females aged ≤45. The objective is to investigate ADIPOR2's functional role through siRNA knockdown experiments in MCF7 and MDA-MB-231 cell lines. Methods included cBioPortal analysis of 2,145 patients aged ≤45 and 353 patients aged >45 to compare ADIPOR2 amplification rates, followed by siRNA transfection to evaluate cell size and viability. Results show that ADIPOR2 amplification is strongly associated with estrogen and progesterone receptor positivity. Knockdown of ADIPOR2 significantly reduced cell size and viability in both MCF7 and MDA-MB-231 cell lines, suggesting its role in maintaining membrane integrity. These findings demonstrate ADIPOR2 as a potential therapeutic target in breast cancer, especially in hormone receptor-positive cases, by disrupting membrane composition and potentially promoting cancer cell apoptosis.
